Cognition Therapeutics Inc
CGTXNasdaqCIK 1455365HealthcareFiscal year ends Dec 31
Reports and events: 108 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2210:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-117948 |
| 2026-08-0711:30 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001104659-26-092362 |
| 2026-08-0620:18 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-092037 |
| 2026-06-2411:39 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-077060 |
| 2026-06-1812:05 ET | 8-K | 5.07 Shareholder vote results | 0001104659-26-075442 |
| 2026-06-0412:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-070345 |
| 2026-05-2111:34 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-064863 |
| 2026-05-0811:30 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001104659-26-057545 |
| 2026-05-0720:24 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-057186 |
| 2026-04-2720:05 ET | DEF 14A | Proxy statementPeriod 2026-06-17 | 0001104659-26-049427 |
| 2026-03-2611:40 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001104659-26-034880 |
| 2026-03-2611:36 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-034876 |
| 2026-03-0212:35 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-021904 |
| 2026-01-2712:37 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-006813 |
| 2025-12-1821:20 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement | 0001104659-25-122555 |
| 2025-11-0612:46 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001104659-25-107402 |
| 2025-11-0612:34 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-107390 |
| 2025-09-2301:58 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-25-092675 |
| 2025-09-1511:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-089737 |
| 2025-08-2821:10 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-25-084845 |
| 2025-08-2620:01 ET | 8-K | 8.01 Other events | 0001104659-25-083059 |
| 2025-08-0721:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-075268 |
| 2025-08-0720:17 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001558370-25-010771 |
| 2025-06-2020:01 ET | 8-K | 5.07 Shareholder vote results | 0001104659-25-061142 |
| 2025-06-0311:39 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-055717 |
| 2025-06-0210:01 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-055089 |
| 2025-05-0811:35 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-045886 |
| 2025-05-0711:45 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001558370-25-006612 |
| 2025-05-0711:36 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-045324 |
| 2025-04-2820:07 ET | DEF 14A | Proxy statementPeriod 2025-06-18 | 0001104659-25-040193 |
| 2025-03-2011:15 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001558370-25-003341 |
| 2025-03-2011:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-025828 |
| 2025-03-1220:05 ET | 8-K | 8.01 Other events | 0001104659-25-022969 |
| 2025-02-2612:09 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-017178 |
| 2025-01-2821:41 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-006732 |
| 2025-01-1316:55 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-002939 |
| 2024-12-1813:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-129619 |
| 2024-11-1312:45 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001558370-24-015436 |
| 2024-11-1312:37 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-117243 |
| 2024-10-0110:02 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-24-104541 |
| 2024-09-1320:01 ET | 8-K | 3.01 Delisting notice | 0001104659-24-099746 |
| 2024-08-2810:26 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-24-093660 |
| 2024-08-0811:16 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001558370-24-011464 |
| 2024-08-0811:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-087001 |
| 2024-07-2912:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-083280 |
| 2024-06-0720:06 ET | 8-K | 5.07 Shareholder vote results | 0001104659-24-069635 |
| 2024-05-0711:45 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001558370-24-006911 |
| 2024-05-0711:39 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-057711 |
| 2024-04-2620:01 ET | DEF 14A | Proxy statementPeriod 2024-06-07 | 0001104659-24-052901 |
| 2024-03-2620:16 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001558370-24-003949 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.